Partner

Articles & Insights / Patient Centric Formats

Chewable Nutraceuticals That Balance Taste Dose and Stability

A chewable succeeds when it delivers the intended nutrients consistently, remains acceptable during storage and can be used comfortably as directed. Taste is one development objective within a wider set of product-quality requirements.

Stabicon Life Sciences3 min read

Accreditations, approvals & registrations

  • Prequalified by WHO, Geneva

    One of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

  • Accredited by ISO/IEC 17025:2017 (NABL)

  • Approved by FSSAI

  • Approved by CDSCO, India

  • Facility Registered with FDA, Karnataka

  • Registered with DSIR

  • Registered with AYUSH

All articles

What this article helps you consider

  • Define the format and user
  • Calculate the available formulation space
  • Address taste and mouthfeel at the source

Define the format and user

Clarify whether the product is a compressed chewable tablet, soft chew, gummy or another format. These systems differ in water content, processing, texture and stability. They should not share a single development specification simply because the consumer chews them.

Set the intended population, serving size, frequency and use instructions early. A high-mineral product may require a large mass that is difficult to accommodate in one acceptable unit. Children and older adults can have different handling and chewing needs. Product design should consider safe and practical use as well as nutrient delivery.

Calculate the available formulation space

Convert declared nutrient amounts into the required masses of salts, premixes or coated ingredients. Add the materials needed for structure, sweetness, flavour and processing. This mass balance establishes how much space remains for sensory improvement. A low elemental fraction in a mineral source can have a major effect on unit size.

For illustration, a mineral ingredient containing 25% elemental mineral requires 400 mg of ingredient to supply 100 mg of that mineral, before accounting for potency and process factors. This example is arithmetic rather than a recommended dose. Use actual ingredient specifications for development and verify permitted nutrient forms and levels in the target market. R21

Address taste and mouthfeel at the source

Bitterness, metallic notes, grittiness and aftertaste can arise from different ingredients. Flavour addition alone may not solve an exposure problem. Compare ingredient forms, particle properties, coatings and sweetener systems while measuring their effects on uniformity and release.

Taste masking can reduce exposure to taste receptors but may also influence nutrient release. A coating that survives chewing differently among users introduces a question that a standard intact-tablet experiment may not fully capture. Define appropriate development tests and avoid claiming better absorption merely because the product is pleasant or disperses rapidly.

Establish physical performance

For compressed products, examine breaking force, friability, disintegration or other relevant performance measures. Soft chews and gummies may require texture measurements suited to their structure, including changes in firmness, stickiness or elasticity. The appropriate tests depend on the actual formulation and intended use.

FDA’s chewable-tablet guidance addresses medicinal products and provides useful discussion of quality attributes such as hardness, disintegration and dissolution. It should be used as a scientific reference with its pharmaceutical scope clearly identified, rather than described as the governing rule for every nutraceutical chewable. R31

Control low dose distribution and storage changes

A high-dose mineral and a low-dose vitamin can be difficult to distribute consistently in the same blend. Evaluate particle size, density, premix design, segregation and processing. Average batch assay does not show whether each unit contains an appropriate share of a low-dose constituent.

Moisture can soften a compressed chewable, harden or destabilise other matrices, change flavour and promote reactions. Track chemical and sensory quality in the intended packaging. For water-containing systems, assess water activity and microbial control according to the product category. The illustration summarises the development objectives as a set of measurable attributes rather than an invented performance score.

Explore the sciencePatient Centric Formats

Designing the whole chewable

DoseTasteTextureStability
Dose & unit size

Calculate ingredient mass from actual potency and elemental content.

Conceptual illustration. Select a topic to explore its role. The visual does not establish formulation performance or prescribe universal regulatory requirements.

Example development attributes for chewable formats. Tests and acceptance criteria depend on composition, format, intended use and the applicable product category.

Confirm acceptability using a suitable protocol

Use a defined sensory approach with clear attributes and appropriate participants. Screen ingredient safety and use conditions before any tasting. Early internal comparisons can help select prototypes but should not be described as consumer validation or clinical evidence. Record the preparation, serving condition and scoring definitions so that results are comparable.

Stabicon can integrate ingredient selection, sensory development, analytical methods and stability testing to create chewable formats with a clear quality basis. The development objective is an acceptable product that consistently meets its intended specification throughout use.

References & further reading

Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.

  1. R14
    FSSAI Food Safety Management Systems Guidance for Food Supplements

    Guidance document, 2018. Practical food-supplement manufacturing and hygiene context; not a replacement for current regulations.

  2. R21
    FSSAI Health Supplements and Nutraceuticals Standards

    Official regulations portal. Verify current amendments, permitted ingredients, levels and category-specific requirements.

  3. R26
    Impact of Deliquescence on the Chemical Stability of Vitamins B1 B6 and C in Powder Blends

    Primary research, 2008. PubMed PMID 18593179. Specific experimental matrices; no universal threshold inferred.

  4. R31
    FDA Quality Attribute Considerations for Chewable Tablets

    Final guidance, August 2018. Medicinal chewable tablets; scientific context for other formats is not regulatory equivalence.

From insight to a defined programme

Bring your next technical question.

Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.

Discuss this topic with Stabicon

Continue reading

Related scientific perspectives.

Stabicon Life Sciences

Science-Led Formulations. Scalable Health Platforms.

Offices

Corporate Office

22, 7th Cross, Jaibharath Nagar, Bengaluru 560 033, Karnataka, India

Research & Development

28, Bommasandra Industrial Area, 4th Phase, Jigani Hobli, Anekal Taluk, Bengaluru 560 099, Karnataka, India

Newsletter

Quarterly briefings on platforms, science & partnerships.

No spam. Request a consent withdrawal at bd@stabicon.com.

Press Kit

Logos, company information & spokesperson details – available from our media team.

Request Press Kit

Accreditations

Prequalified by WHO, GenevaAccredited by ISO/IEC 17025:2017 (NABL)Approved by FSSAIApproved by CDSCO, IndiaFacility Registered with FDA, KarnatakaRegistered with DSIRRegistered with AYUSHOne of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. Product packaging and materials may vary from those shown on our website. We recommend that you do not rely solely on the information presented and that you always read labels, warnings, and directions before using or consuming a product.

© 2026 Stabicon Life Sciences Pvt. Ltd. All rights reserved.

Science-Led Formulations. Scalable Health Platforms.

Admin